Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)

CONCLUSION: The difference in total treatment cost is largely explained by the significantly lower frequency of IVI and annual cost of therapy with DXI, compared with AFL and RAN. INVICOST is the first study comparing treatment costs with AFL, DXI and RAN in France in current clinical practice.PMID:34284605 | DOI:10.1177/11206721211033480

Source: European Journal of Ophthalmology - July 21, 2021 Category: Opthalmology Authors: Pierre Gascon Isabelle Borget Alban Comet Laurence Carton Fr édéric Matonti Laure Dupont-Benjamin Source Type: research